Management presentations to be hosted at 2008 American Association for
Clinical Chemistry Annual Meeting
SUNNYVALE, Calif., July 21 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today invited investors to participate in the Company's Analyst Reception which is being hosted in Washington, D.C. ahead of the 2008 American Association for Clinical Chemistry (AACC) Annual Meeting.
Cepheid speakers will include Chief Executive Officer John Bishop, Chief Medical and Technology Officer David Persing, Chief Operations Officer Humberto Reyes, Senior Vice President of Worldwide Commercial Operations, Rob Koska, and Chief Financial Officer Andrew Miller.
Investors and interested parties are welcome to access the live webcast that will be available starting at 5:30 p.m. Eastern Time on Monday, July 28, 2008. The program is expected to last up to three hours. To access the live webcast, please visit Cepheid's website at http://www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.
Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand
molecular diagnostics company that develops, manufactures, and markets
fully-integrated systems and tests for genetic analysis in the clinical,
industrial and biothreat markets. The Company's systems enable rapid,
sophisticated genetic testing for organisms and genetic-based diseases by
automating otherwise complex manual laboratory procedures. Cepheid's
easy-to-use systems integrate a number of complicated and time-intensive
steps, including sample preparation, DNA amplification and detection, which
enable the analysis of complex biological samples in its proprietary test
cartridges. Through its strong molecular biology capabilities, the Company
is focusing on those applications where rapid molecular testing is
particularly important, such as identifying infectious disease and cancer
in the clinical market; food, agricultural, and environmental testing in
the industrial market; and identifying bio-terrorism agents in the
For Media Inquiries:
Cepheid Corporate Communications
Tel: (408) 400 8377
For Investor Inquiries:
Cepheid Investor Relations
Tel: (408) 400 8329
Copyright©2008 PR Newswire.
All rights reserved